Review of 'Updated aluminum pharmacokinetics following infant exposures through diet and vaccination.'

Author: vinu arumugham

Publication date: 2017-12-27

Bookmark

vinu arumugham2

This study is fundamentally flawed because it ignores aluminum immunotoxicity

Average rating:	    Rated 2 of 5.
Level of importance:	    Rated 1 of 5.
Level of validity:	    Rated 1 of 5.
Level of completeness:	    Rated 1 of 5.
Level of comprehensibility:	    Rated 4 of 5.
Competing interests:	None

Reviewed article

Record: found
Abstract: found
Article: not found

Updated aluminum pharmacokinetics following infant exposures through diet and vaccination.

B. T. King, Mark O. Walderhaug, M. Heß … (2011)

Aluminum is a ubiquitous element that is released naturally into the environment via volcanic activity and the breakdown of rocks on the earth's surface. Exposure of the general population to aluminum occurs primarily through the consumption of food, antacids, and buffered analgesics. Exposure to aluminum in the general population can also occur through vaccination, since vaccines often contain aluminum salts (frequently aluminum hydroxide or aluminum phosphate) as adjuvants. Because concerns have been expressed by the public that aluminum in vaccines may pose a risk to infants, we developed an up-to-date analysis of the safety of aluminum adjuvants. Keith et al. [1] previously analyzed the pharmacokinetics of aluminum for infant dietary and vaccine exposures and compared the resulting body burdens to those based on the minimal risk levels (MRLs) established by the Agency for Toxic Substances and Disease Registry. We updated the analysis of Keith et al. [1] with a current pediatric vaccination schedule [2]; baseline aluminum levels at birth; an aluminum retention function that reflects changing glomerular filtration rates in infants; an adjustment for the kinetics of aluminum efflux at the site of injection; contemporaneous MRLs; and the most recent infant body weight data for children 0-60 months of age [3]. Using these updated parameters we found that the body burden of aluminum from vaccines and diet throughout an infant's first year of life is significantly less than the corresponding safe body burden of aluminum modeled using the regulatory MRL. We conclude that episodic exposures to vaccines that contain aluminum adjuvant continue to be extremely low risk to infants and that the benefits of using vaccines containing aluminum adjuvant outweigh any theoretical concerns. Published by Elsevier Ltd.

0 comments Cited 9 times     Rated 2 of 5. – based on 1 reviews

(Latest)

Bookmark

Review information

DOI:: 10.14293/S2199-1006.1.SOR-CHEM.AG04GF.v1.RDBMSO

License:

This work has been published open access under Creative Commons Attribution License CC BY 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com.

ScienceOpen disciplines:	Chemistry
Keywords:	Adjuvants, Immunologic, adverse effects, Aluminum, adverse effects, pharmacokinetics, Humans, Vaccination, adverse effects

Review text

This study is fundamentally flawed because it ignores aluminum immunotoxicity.

Details:

Safety studies of aluminum in vaccines lack immunotoxicity analysis of this immunological adjuvant: Ignorance or deception?

https://doi.org/10.5281/zenodo.1117241

Comments

Comment on this review

Version and Review History

Article

Reviewed by vinu arumugham